

Fracture risk reduction with use of dipeptidyl peptidase-4 inhibitors

Citation for published version (APA):

Driessen, J. H. M., Knapen, L. M., Geusens, P. P. M. M., & van den Bergh, J. P. W. (2017). Fracture risk reduction with use of dipeptidyl peptidase-4 inhibitors: is there immortal time bias? *Osteoporosis International*, 28(8), 2429-2430. <https://doi.org/10.1007/s00198-017-4120-2>

Document status and date:

Published: 01/08/2017

DOI:

[10.1007/s00198-017-4120-2](https://doi.org/10.1007/s00198-017-4120-2)

Document Version:

Publisher's PDF, also known as Version of record

Document license:

Taverne

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

Fracture risk reduction with use of dipeptidyl peptidase-4 inhibitors: is there immortal time bias?

J. H. M. Driessen^{1,2,3,4} · L. M. Knapen^{1,3} · P. P. M. M. Geusens^{5,6} · J. P. W. van den Bergh^{2,5,6,7}

Received: 31 May 2017 / Accepted: 8 June 2017 / Published online: 13 July 2017
© International Osteoporosis Foundation and National Osteoporosis Foundation 2017

Dear Editor,

Dombrowski et al. [1] report a 33% reduced risk of bone fracture and a 57% reduced risk of hip fracture with use of dipeptidyl peptidase-4 inhibitors (DPP4-Is) and metformin as compared to metformin-only use. The identified protective effect is in contrast with recent literature on this topic, which has not shown an association [2–4]. In view of this difference, we are concerned that the reported relationship may be affected by immortal time bias [5]. Immortal time bias leads to an effect in favour of the studied drug, which corresponds with the results found in the study by Dombrowski et al. [1].

A response to these comments can be found at doi:10.1007/s00198-017-4139-4.

✉ J. H. M. Driessen
annemariet.driessen@mumc.nl

¹ CAPHRI School for Public Health and Primary Care, Maastricht University, Maastricht, The Netherlands

² NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht University, Maastricht, The Netherlands

³ Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center+, Maastricht, The Netherlands

⁴ Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences, Utrecht, The Netherlands

⁵ Biomedical Research Centre, Hasselt University, Agoralaan, Gebouw D, 3590 Diepenbeek, Belgium

⁶ Department of Internal Medicine, Subdivision Rheumatology, CAPHRI, Maastricht University Medical Centre+, Maastricht, The Netherlands

⁷ Department of Internal Medicine, VieCuri Medical Centre, P.O. Box 1926, 5900 BX Venlo, The Netherlands

In the study by Dombrowski et al. [1], the start of follow-up is not fully clear. In the methods section, it is mentioned that the index date is defined based on the first DPP4-I (for the DPP4-I users) or the first metformin (for the metformin-only users) prescription, respectively. This suggests that the time between the first metformin prescription and the first DPP4-I prescription is excluded from the analysis. As a consequence, patients have to survive event-free until the time of the first DPP4-I prescription, which causes immortal time bias.

However, the study outcome was defined as rate of bone fractures within 5 years of starting metformin therapy, which suggests that patients (both DPP4-I users and the metformin-only users) were followed from the first metformin prescription onwards. This may only result in immortal time bias if the time from the first metformin prescription until the first DPP4-I prescription is classified as DPP4-exposed instead of unexposed. A time-dependent analysis, in which the time until the DPP4-I prescription is classified as unexposed and the time from the first DPP4-I prescription onwards as exposed, would solve this potential problem.

In conclusion, we would kindly ask the authors to provide some more information on the study design as it is important to know what date was used for both exposure groups to determine start of follow-up. In particular, if the date of the first metformin prescription was used to determine follow-up, it is critical to know whether the time from the first metformin prescription to the first DPP4-I prescription was classified as DPP4-exposed or unexposed.

Compliance with ethical standards

Conflicts of interest JD, LK, PG and JvB declare that they have no conflicts of interest.

References

1. Dombrowski S, Kostev K, Jacob L (2017) Use of dipeptidyl peptidase-4 inhibitors and risk of bone fracture in patients with type 2 diabetes in Germany—a retrospective analysis of real-world data. *Osteoporos Int*. doi:[10.1007/s00198-017-4051-y](https://doi.org/10.1007/s00198-017-4051-y)
2. Mamza J, Marlin C, Wang C, Chokkalingam K, Idris I (2016) DPP-4 inhibitor therapy and bone fractures in people with type 2 diabetes—a systematic review and meta-analysis. *Diabetes Res Clin Pract* 116: 288–298
3. Mosenzon O, Wei C, Davidson J, Scirica BM, Yanuv I, Rozenberg A et al (2015) Incidence of fractures in patients with type 2 diabetes in the SAVOR-TIMI 53 trial. *Diabetes Care* 38(11):2142–2150
4. Driessen JH, van den Bergh JP, van Onzenoort HA, Henry RM, Leufkens HG, de Vries F (2017) Long-term use of dipeptidyl peptidase-4 inhibitors and risk of fracture: a retrospective population-based cohort study. *Diabetes Obes Metab* 19(3):421–428
5. Suissa S (2007) Immortal time bias in observational studies of drug effects. *Pharmacoepidemiol Drug Saf* 16(3):241–249